Shares of Joint Corp (NASDAQ:JYNT) have received a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $23.40.
JYNT has been the topic of several recent analyst reports. Maxim Group reaffirmed a “buy” rating and set a $22.00 target price on shares of Joint in a research report on Friday, May 8th. TheStreet lowered Joint from a “b-” rating to a “c+” rating in a report on Friday, April 17th. Zacks Investment Research lowered Joint from a “hold” rating to a “sell” rating in a report on Thursday, June 11th. DA Davidson increased their price objective on Joint from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Finally, Craig Hallum assumed coverage on Joint in a report on Thursday, June 25th. They issued a “buy” rating and a $24.00 price objective on the stock.
NASDAQ:JYNT traded up $1.27 during mid-day trading on Thursday, hitting $15.14. 71,400 shares of the company’s stock traded hands, compared to its average volume of 136,662. The company has a fifty day moving average of $14.46 and a 200 day moving average of $14.24. Joint has a twelve month low of $7.67 and a twelve month high of $21.80. The company has a market capitalization of $193.39 million, a P/E ratio of 68.82 and a beta of 1.16. The company has a debt-to-equity ratio of 2.02, a quick ratio of 1.15 and a current ratio of 1.15.
Joint (NASDAQ:JYNT) last announced its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.01). Joint had a net margin of 6.20% and a return on equity of 66.44%. The business had revenue of $13.64 million for the quarter, compared to analyst estimates of $13.03 million. On average, research analysts expect that Joint will post 0.04 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its stake in shares of Joint by 9.9% in the first quarter. Invesco Ltd. now owns 11,211 shares of the company’s stock worth $122,000 after buying an additional 1,013 shares during the last quarter. Aigen Investment Management LP boosted its position in Joint by 85.9% during the first quarter. Aigen Investment Management LP now owns 2,418 shares of the company’s stock worth $26,000 after purchasing an additional 1,117 shares in the last quarter. Citigroup Inc. boosted its position in Joint by 42.7% during the first quarter. Citigroup Inc. now owns 3,738 shares of the company’s stock worth $41,000 after purchasing an additional 1,119 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in Joint by 120.9% during the first quarter. BNP Paribas Arbitrage SA now owns 4,019 shares of the company’s stock worth $44,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Joint by 1.7% during the first quarter. Wells Fargo & Company MN now owns 137,313 shares of the company’s stock worth $1,490,000 after purchasing an additional 2,248 shares in the last quarter. Hedge funds and other institutional investors own 76.24% of the company’s stock.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More: Penny Stocks, What You Need To Know
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.